Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vella

Showing results (131-140 of 171) with videos related to

Pageof 18
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
Clinical ManifestationsDarren M Lipnicki, Ashleigh S Vella, Erico Costa, et al.
Journal of Chemotherapy (Florence, Italy)|April 13, 2011
Adherence and genotypic drug resistance mutations in HIV-1-infected patients failing current antiretroviral therapyG d'Ettorre, G Forcina, G Ceccarelli, et al.
Lancet (London, England)|December 16, 1998
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study GroupA Mocroft, S Vella, T L Benfield, et al.
Antiviral Research|September 7, 2000
Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatmentS Vella, M C Galluzzo, G Giannini, et al.
AIDS (London, England)|June 21, 2001
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individualsA I Veldkamp, G J Weverling, J M Lange, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Public HealthRory Chen, Vibeke S Catts, Ashleigh S Vella, et al.
JAMA|April 17, 1998
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia StudyJ S Montaner, P Reiss, D Cooper, et al.
AIDS (London, England)|October 9, 1998
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapyJ M Raboud, J S Montaner, B Conway, et al.
AIDS (London, England)|December 2, 1998
Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependentS Rae, J M Raboud, B Conway, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 15, 2017
Cytomegalovirus (CMV) DNA load in breast milk of human immunodeficiency virus-positive women and infant CMV infection acquisition are not reduced with long-term antiretroviral therapyM Giuliano, M F Pirillo, G Liotta, et al.
Pageof 18

Showing results (131-140 of 171) with videos related to

Sort By:
Pageof 18
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
Clinical ManifestationsDarren M Lipnicki, Ashleigh S Vella, Erico Costa, et al.
Journal of Chemotherapy (Florence, Italy)|April 13, 2011
Adherence and genotypic drug resistance mutations in HIV-1-infected patients failing current antiretroviral therapyG d'Ettorre, G Forcina, G Ceccarelli, et al.
Lancet (London, England)|December 16, 1998
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study GroupA Mocroft, S Vella, T L Benfield, et al.
Antiviral Research|September 7, 2000
Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatmentS Vella, M C Galluzzo, G Giannini, et al.
AIDS (London, England)|June 21, 2001
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individualsA I Veldkamp, G J Weverling, J M Lange, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Public HealthRory Chen, Vibeke S Catts, Ashleigh S Vella, et al.
JAMA|April 17, 1998
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia StudyJ S Montaner, P Reiss, D Cooper, et al.
AIDS (London, England)|October 9, 1998
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapyJ M Raboud, J S Montaner, B Conway, et al.
AIDS (London, England)|December 2, 1998
Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependentS Rae, J M Raboud, B Conway, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 15, 2017
Cytomegalovirus (CMV) DNA load in breast milk of human immunodeficiency virus-positive women and infant CMV infection acquisition are not reduced with long-term antiretroviral therapyM Giuliano, M F Pirillo, G Liotta, et al.
Pageof 18